Truncating SOX9 Alterations Are Heterozygous Null Alleles in Genome-Stable Colorectal Cancer
G.N. Duronio,
X. Liang,
P. Hebbar,
M. Islam,
S. Spisak,
N.S. Sethi
Affiliations
G.N. Duronio
Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
X. Liang
Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
P. Hebbar
Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
M. Islam
Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
S. Spisak
Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts
N.S. Sethi
Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Cancer Program, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University, Cambridge, Massachusetts; Department of Medical Oncology, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; Correspondence: Address correspondence to: Nilay Sethi, MD, PhD, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 812, Boston, Massachusetts 02215.
